Articles

The Mission of the Association for Value-Based Cancer Care
The Mission of the Association for Value-Based Cancer Care
By Burt Zweigenhaft, PhD, D.Litt
Videos
Program Chair, Burt Zweigenhaft, describes the main mission of the Association for Value-Based Cancer Care.
Read More
AVBCC Essential for Quality Practices
AVBCC Essential for Quality Practices
By Vicki Kennedy, LCSW
Videos
Vicki Kennedy supports the position that professional associations are essential to quality practices. The Association for Value-Based Cancer Care (AVBCC) has been critical in advancing the discussion and solutions surrounding value-based care.
Read More
AVBCC Supports Collaboration
AVBCC Supports Collaboration
By Gary M. Owens, MD
Videos
Gary Owens emphasizes the importance of AVBCC as the only organization that brings together all the different stakeholders in oncology care—payers, care providers, drug developers, investment community, government agency reps, and employers.
Read More
Leveraging Professional Membership to Improve Patient Care
Leveraging Professional Membership to Improve Patient Care
By Linda D. Bosserman, MD, FACP
Videos
Membership in organizations such as ASCO, AVBCC, COA, and ACCC allows clinicians to have a voice in policy and legislation that directly affects our patients, says Dr. Bosserman.
Read More
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
By Loretta Fala
Drug Updates
May 2015, Vol 6, No 4
One of the most fear-inducing side effects of chemotherapy is nausea and vomiting. Without appropriate antiemetic prophylaxis, 70% to 80% of all patients with cancer who receive chemotherapy experience nausea and/or vomiting. Consequently, preventing and managing chemotherapy­induced nausea and vomiting (CINV) is a crucial part of care planning for patients with cancer.
Read More
CancerLinQ Moves to Its Patient Data-Gathering Clinical Phase
By Rosemary Frei, MSc
Oncology
May 2015, Vol 6, No 4
The American Society of Clinical Oncology (ASCO) and a German company called SAP are launching the clinical phase of ASCO’s big-data initiative—CancerLinQ. This clinical phase is focused on gathering and analyzing data from the 97% of US patients with cancer who do not participate in clinical trials.
Read More

Page 195 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.